BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30799130)

  • 1. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.
    Balakrishnan AS; Washington SL; Meng MV; Porten SP
    Clin Genitourin Cancer; 2019 Jun; 17(3):e461-e471. PubMed ID: 30799130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
    Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
    Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
    J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Brake M; Loertzer H; Horsch R; Keller H
    Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical cystectomy compared to intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer - is there a long-term survival difference? A Swedish nationwide analysis.
    Wang EY; Larsson U; Gårdmark T; Malmström PU
    Scand J Urol; 2021 Feb; 55(1):46-52. PubMed ID: 33305681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
    Robins DJ; Sui W; Matulay JT; Ghandour R; Anderson CB; DeCastro GJ; McKiernan JM
    Urology; 2017 May; 103():149-153. PubMed ID: 28163086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
    Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
    Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
    Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
    Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer.
    Washington SL; Gregorich SE; Meng MV; Suskind AM; Porten SP
    Cancer Med; 2020 Nov; 9(22):8310-8317. PubMed ID: 32869516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
    Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
    Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review.
    Mori K; Miura N; Babjuk M; Karakiewicz PI; Mostafaei H; Laukhtina E; Quhal F; Motlagh RS; Pradere B; Kimura S; Egawa S; Shariat SF
    Urol Oncol; 2020 Oct; 38(10):774-782. PubMed ID: 32654948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline adherence for radical cystectomy significantly affects survival outcomes in non-muscle-invasive bladder cancer patients.
    Kayama E; Shigeta K; Kikuchi E; Ogihara K; Hakozaki K; Iwasawa T; Kamisawa K; Kanai K; Ide H; Hara S; Mizuno R; Oya M
    Jpn J Clin Oncol; 2021 Aug; 51(8):1303-1312. PubMed ID: 34009374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
    Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
    Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.